Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
33
BICX Quote, Financials, Valuation and Earnings
Last price:
$0.31
Seasonality move
:
5.09%
Day range:
$0.31 - $0.31
52-week range:
$0.20 - $0.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.19x
P/B ratio:
--
Volume:
3.3K
Avg. volume:
7.8K
1-year change:
-25.03%
Market cap:
$7.3M
Revenue:
$7.7K
EPS (TTM):
-$0.32
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, BioCorRx, Inc. has 158.07% upside to fair value with a price target of -- per share.
BICX vs. S&P 500
-
Over the past 5 trading days, BioCorRx, Inc. has overperformed the S&P 500 by 20.97% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
BioCorRx, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BioCorRx, Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter BioCorRx, Inc. reported revenues of $635.2K.
Earnings Growth
-
BioCorRx, Inc. has grown year-over-year earnings for 4 quarters straight. In the most recent quarter BioCorRx, Inc. reported earnings per share of -$0.11.
Enterprise value:
15.6M
EV / Invested capital:
--
Price / LTM sales:
5.19x
EV / EBIT:
--
EV / Revenue:
16.40x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-9.16x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$378.6K
Return On Assets:
-96.74%
Net Income Margin (TTM):
-449.77%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-306.3%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $153.1K | $26.6K | $948.4K | -- | $635.2K | |
| Gross Profit | -$28.1K | -$147.7K | $378.6K | -$16.1K | $204.4K | |
| Operating Income | -$4.1M | -$4.8M | -$5.4M | -$1.7M | -$1.9M | |
| EBITDA | -$4M | -$4.7M | -$5.2M | -$1.6M | -$1.9M | |
| Diluted EPS | -$0.49 | -$0.52 | -$0.32 | -$0.14 | -$0.11 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $971.6K | $333K | $245.8K | $353.1K | $1.5M | |
| Total Assets | $1.6M | $819.2K | $534.4K | $643.6K | $7.5M | |
| Current Liabilities | $4.1M | $4.5M | $5.9M | $8.2M | $15M | |
| Total Liabilities | $7.4M | $8M | $9.8M | $12.6M | $20.3M | |
| Total Equity | -$5.8M | -$7.2M | -$9.3M | -$12M | -$12.8M | |
| Total Debt | $4.4M | $3.5M | $3.8M | $4.4M | $5.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$1.8M | -$1.4M | -$1.7M | -$357.5K | -$634.4K | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $1.9M | $1.2M | $2M | $349.3K | $810.3K | |
| Free Cash Flow | -$1.8M | -$1.4M | -$1.7M | -$357.5K | -$634.4K | |
BICX
Sector
Market Cap
$7.3M
$23.4M
Price % of 52-Week High
62%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
-23.92%
-1.64%
1-Year Price Total Return
-25.03%
-21.81%
Beta (5-Year)
0.414
0.504
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.27
200-day SMA
Sell
Level
$0.36
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$0.32
Relative Strength Index (RSI14)
Buy
Level
50.17
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-40.7647
50-day SMA
Sell
Level
$0.33
MACD (12, 26)
Sell
Level
-0.02
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-370.5742)
Sell
CA Score
(Annual)
Level (-192.3981)
Buy
Beneish M-Score
(Annual)
Level (-56.5973)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (267.6575)
Sell
Piotroski F Score
(Annual)
Level (2)
Buy
Quality Ratio Score
Level (5)
Sell
Fundamental Score
Level (0)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BioCorRx, Inc. engages in the provision of alcoholism and opioid addiction treatment. It offers treatment philosophy that combines medical intervention and a proprietary cognitive behavioral therapy program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatments. It also engages in the research and development of sustained release naltrexone products for the treatment of addiction and other possible disorders. The company was founded by Neil Terrence Muller and George O'Neill on January 28, 2008 and is headquartered in Anaheim, CA.
Stock Forecast FAQ
In the current month, BICX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BICX average analyst price target in the past 3 months is --.
-
Where Will BioCorRx, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that BioCorRx, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About BioCorRx, Inc.?
Analysts are divided on their view about BioCorRx, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BioCorRx, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is BioCorRx, Inc.'s Price Target?
The price target for BioCorRx, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BICX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BioCorRx, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of BICX?
You can purchase shares of BioCorRx, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BioCorRx, Inc. shares.
-
What Is The BioCorRx, Inc. Share Price Today?
BioCorRx, Inc. was last trading at $0.31 per share. This represents the most recent stock quote for BioCorRx, Inc.. Yesterday, BioCorRx, Inc. closed at $0.31 per share.
-
How To Buy BioCorRx, Inc. Stock Online?
In order to purchase BioCorRx, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get BICX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BICX
Sector
P/E ratio
--
23.34x
PEG ratio
--
-0.01x
P/B ratio
--
1.72x
Price / LTM sales
5.19x
1.51x
Growth Metrics
BICX
Sector
Revenue growth
4306.38%
3.21%
Earnings growth
22.58%
10.12%
Revenue (5-year growth)
-49.79%
6.27%
Earnings forecast
--
-$0.19
Profitability
BICX
Sector
Profitability FY 2024
-$89.3K
$2.7M
Return on invested capital
--
-33.62%
Return on assets
-96.74%
-29.68%
Return on equity
--
-38.89%
Earnings Date
Last Earnings Date
Feb
13
Next Earnings Date
Feb
13
Estimated Next Earnings Date
May
15
Balance Sheet
BICX
Sector
Total cash
$287.7K
$25M
Short term investments
--
$23.9M
Total assets
$385.9K
$72.8M
Long term debt
$5.2M
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
40
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
91
TDC alert for Feb 12
Teradata Corp. [TDC] is down 11.64% over the past day.
Buy
72
DIOD alert for Feb 13
Diodes, Inc. [DIOD] is down 7.63% over the past day.
Buy
77
VRT alert for Feb 12
Vertiv Holdings Co. [VRT] is down 4.79% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
